[11] Candida hyphae have also been shown to penetrate dentinal tubules along cracks of tooth surfaces, enabling the organism to invade dental hard tissues.[12] Apart from the aforementioned biological factors, the microbial cell surface hydrophobicity (CSH), which contributes to hydrophobic interactions between cells and surfaces, is thought to be an important non-biological
factor associated in the adherence of Candida to inert surfaces.[13] Studies have also shown that hydrophobic yeast are more virulent than their hydrophilic counterparts.[14, 15] Statistically significant correlations between CSH and candidal adhesion to BEC and denture acrylic surfaces have also been reported.[16, 17] Transient exposure
to antifungals may affect the aforementioned traits of Vorinostat clinical trial candidal adhesion. For instances, it has been shown that foregoing attributes of Candida albicans were significantly reduced after limited exposure to subcidal concentrations of antifungal agents. The suppression of candidal growth that occurs following limited exposure to antifungal agents, as in the oral environment, MK-2206 in vitro has been described as the postantifungal effect (PAFE). This phenomenon has been mainly studied with C. albicans isolates. It has been documented that the knowledge of PAFE, in tandem with minimum inhibitory concentration (MIC) values of a drug, would be clinically useful in evaluating new dosage regimens of a drug.[18] Furthermore, transient exposure to antifungal agents may also affect such virulence factors of Candida pertaining to their adhesion.[19, 20] Nystatin (i.e. oral suspensions, ointments, pastilles, creams) is a widely obtainable and a frequently used SB-3CT antifungal agent available for topical treatment of various types of oral candidosis ranging from pseudomembranous, erythematous to denture-induced variants of oral candidosis. However, the diluents effect of saliva
and the cleansing effect of the oral musculature in the oral cavity tend to reduce the availability of nystatin below that of the effective therapeutic concentrations, thereby compromising its therapeutic efficacy. Hence, the pathogenic Candida may undergo a brief exposure to topically applied antifungal drugs, while thereafter, the drug concentration is likely to be subtherapeutic,[18] a scenario all too familiar in the niches of the oral cavity, which is similar to the phenomena as in PAFE. To our knowledge, there is no information on either the PAFE or its association with the adhesion-related attributes of oral C. dubliniensis isolates following brief exposure to subtherapeutic concentrations of nystatin. Hence, taken together the foregoing information, as well as the findings of a recent prevalence study where oral C.